Latest & greatest articles for bupropion

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on bupropion or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on bupropion and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for bupropion

1. Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness

Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness | CADTH.ca Find the information you need Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness Nicotine Replacement Therapy, Bupropion and Varenicline for Tobacco Cessation: A Review of Clinical Effectiveness (...) Published on: March 8, 2016 Project Number: RC0747-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of nicotine replacement therapy versus bupropion or varenicline in the general population of tobacco users? What is the comparative clinical effectiveness of nicotine replacement therapy, bupropion or varenicline versus placebo in the general population of tobacco users? Key Message Ten relevant

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

2. Bupropion

Bupropion Top results for bupropion - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for bupropion The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

3. Naltrexone?bupropion for managing overweight and obesity

Naltrexone?bupropion for managing overweight and obesity Naltre Naltrex xone–bupropion for managing one–bupropion for managing o ov verweight and obesity erweight and obesity T echnology appraisal guidance Published: 12 December 2017 nice.org.uk/guidance/ta494 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Naltrexone–bupropion for managing overweight and obesity (TA494) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 17Contents Contents 1 Recommendations 4 2 The technology 5 3 Committee discussion 6

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

4. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial Full Text available with Trip Pro

Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial Quitting smoking is enhanced by the use of pharmacotherapies, but concerns have been raised regarding the cardiovascular safety of such medications.To compare the relative cardiovascular safety risk of smoking cessation treatments.A double-blind, randomized, triple-dummy, placebo- and active-controlled trial (Evaluating Adverse Events in a Global Smoking Cessation Study [EAGLES]) and its (...) nontreatment extension trial was conducted at 140 multinational centers. Smokers, with or without established psychiatric diagnoses, who received at least 1 dose of study medication (n = 8058), as well as a subset of those who completed 12 weeks of treatment plus 12 weeks of follow up and agreed to be followed up for an additional 28 weeks (n = 4595), were included.Varenicline, 1 mg twice daily; bupropion hydrochloride, 150 mg twice daily; and nicotine replacement therapy, 21-mg/d patch with tapering.The

2018 EvidenceUpdates

5. Concurrent Bupropion / Varenicline for Smoking Cessation

Concurrent Bupropion / Varenicline for Smoking Cessation Concurrent Bupropion / Varenicline for Smoking Cessation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Concurrent Bupropion / Varenicline (...) varenicline alone or varenicline paired with bupropion. Some participants who would otherwise have failed at their quit smoking attempt could be "rescued" by switching to alternative pharmacotherapies. The proposed study will evaluate the combination treatment against varenicline alone in an adaptive trial design Condition or disease Intervention/treatment Phase Nicotine Dependence Drug: Varenicline Drug: Bupropion Drug: Nicotine patches Drug: Nicotine Inhaler Phase 3 Study Design Go to Layout table

2011 Clinical Trials

6. Benefits and harms of Mysimba© (naltrexone-bupropion) in the management of overweight and obesity: a systematic review and meta-analysis of unpublished clinical study reports

Benefits and harms of Mysimba© (naltrexone-bupropion) in the management of overweight and obesity: a systematic review and meta-analysis of unpublished clinical study reports Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2018 PROSPERO

7. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers Full Text available with Trip Pro

Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers Linden K, Jormanainen V, Linna M, Sintonen H, Wilson K, Kotomaki T Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of varenicline compared with bupropion or no aid for smoking cessation in Finland. The authors concluded that varenicline was more effective and resulted in cost savings

2010 NHS Economic Evaluation Database.

8. Brain Responses to Cigarette-Related and Emotional Images in Smokers During Smoking Cessation: No Effect of Varenicline or Bupropion on the Late Positive Potential. Full Text available with Trip Pro

Brain Responses to Cigarette-Related and Emotional Images in Smokers During Smoking Cessation: No Effect of Varenicline or Bupropion on the Late Positive Potential. Varenicline and bupropion are two effective smoking cessation pharmacotherapies. Researchers have hypothesized that they might be effective, in part, because they reduce cue reactivity and cue-induced cravings. Here, we used event-related potentials (ERPs) to directly measure brain responses to cigarette-related and other (...) motivationally relevant images during a pharmacologically aided quit attempt.Smokers involved in a 12-week placebo-controlled double-blind clinical trial of smoking cessation medications (varenicline, bupropion, placebo) took part in the study. We assessed participants at two time points: 24 h (n = 140) and 4 weeks (n = 176) after the quit date. At both sessions, we measured the amplitude of the late positive potential (LPP), an ERP component reliably associated with motivational relevance, and self-reported

2019 Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco Controlled trial quality: uncertain

9. Combination Varenicline/Bupropion Treatment Benefits Highly Dependent Smokers in an Adaptive Smoking Cessation Paradigm Full Text available with Trip Pro

Combination Varenicline/Bupropion Treatment Benefits Highly Dependent Smokers in an Adaptive Smoking Cessation Paradigm This study replicated and extended results of a previous trial, which found that combination varenicline/bupropion treatment increased smoking abstinence in smokers who were male, highly dependent, and who did not respond to prequit nicotine patch treatment with a >50% reduction in expired-air carbon monoxide in the first week.One hundred and twenty-two male nicotine patch (...) nonresponders and 52 responders were identified. Smokers in each group were randomized to receive 12 weeks of varenicline plus bupropion treatment versus varenicline plus placebo. The primary outcome was continuous smoking abstinence at weeks 8-11 after the target quit date.For smokers with a high level of dependence, judged by having a baseline Fagerstrom Test for Nicotine Dependence (FTND) score ≥ 6 and cigarette consumption ≥ 20/d, combination varenicline/bupropion treatment increased the abstinence rate

2016 Nicotine & Tobacco Research Controlled trial quality: uncertain

10. Neuropsychiatric Safety and Efficacy of Varenicline, Bupropion, and Nicotine Patch in Smokers With Psychotic, Anxiety, and Mood Disorders in the EAGLES Trial. Full Text available with Trip Pro

Neuropsychiatric Safety and Efficacy of Varenicline, Bupropion, and Nicotine Patch in Smokers With Psychotic, Anxiety, and Mood Disorders in the EAGLES Trial. Neuropsychiatric safety and relative efficacy of varenicline, bupropion, and transdermal nicotine patch (NRT) in those with psychiatric disorders are of interest.We performed secondary analyses of safety and efficacy outcomes by psychiatric diagnosis in EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study), a 12-week (...) , randomized, double-blind, triple-dummy, placebo- and active (NRT)-controlled trial of varenicline and bupropion with 12-week follow-up, in a subset population, n = 4092, with a primary psychotic (n = 390), anxiety (n = 792), or mood (n = 2910) disorder. Primary end-point parameters were incidence of prespecified moderate and severe neuropsychiatric adverse events (NPSAEs) and weeks 9 to 12 continuous abstinence rates (9-12CAR).The observed NPSAE incidence across treatments was 5.1% to 6.3% in those

2019 Journal of Clinical Psychopharmacology Controlled trial quality: predicted high

11. Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland. (Abstract)

Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland. To assess the cost-utility of vortioxetine versus relevant comparators (agomelatine, bupropion SR, sertraline, and venlafaxine XR) in the finnish setting in major depressive disorder (MDD) patients with inadequate response to selective serotonin- /serotonin-norepinephrine reuptake inhibitors.A one-year analysis was conducted using

2016 Expert review of pharmacoeconomics & outcomes research

12. The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy. Full Text available with Trip Pro

The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy. Weight management medications increase the likelihood that patients will achieve clinically meaningful improvements in cardiovascular, metabolic and other weight-related measures of health. However, the weight loss achieved with any weight management intervention can vary widely among individuals, and patients who do not respond to pharmacotherapy by achieving clinically (...) meaningful weight loss should discontinue therapy. We characterized 1-year weight loss in the phase 3 clinical trial program of the weight management medication, naltrexone/bupropion 32/360 mg (NB), as well as the relationship between early weight loss and long-term weight loss, particularly with respect to participants who achieved the clinically recommended threshold of ⩾5% weight loss by Week 16.Data from participants from each of the four phase 3, randomized, placebo-controlled, 56-week clinical

2016 International Journal of Obesity Controlled trial quality: uncertain

13. An RCT with the combination of varenicline and bupropion for smoking cessation: clinical implications for front line use. Full Text available with Trip Pro

An RCT with the combination of varenicline and bupropion for smoking cessation: clinical implications for front line use. Despite the availability of several efficacious smoking cessation treatments, fewer than 25% of smokers who quit remain abstinent 1 year post-treatment. This study aimed to determine if varenicline and bupropion combination treatment would result in higher abstinence rates than varenicline alone.A double-blind, randomized, parallel-group smoking cessation clinical trial (...) in a 3 : 1 (active: Placebo) ratio to 12 weeks of treatment as follows: placebo (n = 56), varenicline (Var; n = 166), and varenicline + bupropion (Combo; n = 163).A priori primary outcome: prolonged abstinence at 12 months.7-day point prevalence abstinence and continuous abstinence; all abstinence measures at end of treatment and 6-month follow-ups.Intention-to-treat analysis: the Combo group (n = 163) failed to demonstrate superiority to the Var group (n = 166) for prolonged abstinence at 12 months

2018 Addiction (Abingdon, England) Controlled trial quality: predicted high

14. Prolonged release naltrexone and bupropion (Contrave) for the management of obesity

Prolonged release naltrexone and bupropion (Contrave) for the management of obesity Prolonged release naltrexone and bupropion (Contrave) for the management of obesity Prolonged release naltrexone and bupropion (Contrave) for the management of obesity NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Prolonged release (...) naltrexone and bupropion (Contrave) for the management of obesity. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Bupropion; Dopamine Uptake Inhibitors; Drug Combinations; Naltrexones; Narcotic Antagonists; Obesity; Weight Loss Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning

2013 Health Technology Assessment (HTA) Database.

15. Mysimba - naltrexone / bupropion

Mysimba - naltrexone / bupropion 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 18 December 2014 EMA/805547/2015 Committee for Medicinal Products for Human Use (CHMP) Mysimba (naltrexone/bupropion) Procedure No. EMEA/H/C/003687 Applicant: Orexigen Therapeutics Ireland Limited Assessment report for an initial marketing (...) /A Not applicable NCA Noncompartmental analysis NB Naltrexone hydrochloride /Bupropion hydrochloride combination NB16 Naltrexone PR 16 mg/Bupropion PR 360 mg NB32 Naltrexone PR 32 mg/Bupropion PR 360 mg NB48 Naltrexone PR 48 mg/Bupropion PR 360 mg ng Nanogram NICE The National Institute for Health and Care Excellence NNH Number needed to harm NNT Number needed to treat NOS Not otherwise specified OCT2 Organic Cation Transporter-2 PAWC Pharmacologically weighted composite PBO Placebo PCS Potentially clinically

2015 European Medicines Agency - EPARs

16. Efficacy and safety of bupropion hydrochloride extended-release versus escitalopram oxalate in Chinese patients with major depressive disorder: Results from a randomized, double-blind, non-inferiority trial. (Abstract)

Efficacy and safety of bupropion hydrochloride extended-release versus escitalopram oxalate in Chinese patients with major depressive disorder: Results from a randomized, double-blind, non-inferiority trial. This study evaluated the non-inferiority of bupropion extended-release (XL) compared to escitalopram for acute-phase treatment of Chinese patients with major depressive disorder (MDD).This randomized (1:1), double-blind, active-control study conducted between February 2015 and October 2016 (...) included patients with MDD (DSM-IV) (N = 538). The treatment phase had three dose levels (level 1 [Week 1], level 2 [Week 2-4], and level 3 [Week 5-8]), which included either bupropion XL 150 mg, 300 mg, 300 mg or escitalopram 10 mg, 10 mg, 10-20 mg (once-daily), respectively. Primary outcome was mean change from baseline in Hamilton Depression Rating Scale-17 (HAMD-17) total score at Week 8.Overall, 534 patients (bupropion XL, n = 266; escitalopram, n = 268) received at least one dose of study

2019 Journal of Affective Disorders Controlled trial quality: uncertain

17. Varenicline and Bupropion for Smoking Cessation

Varenicline and Bupropion for Smoking Cessation Varenicline and Bupropion for Smoking Cessation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Varenicline and Bupropion for Smoking Cessation (CHANBAN (...) and Translational Science Institute Information provided by (Responsible Party): Jon Ebbert, Mayo Clinic Study Details Study Description Go to Brief Summary: This study provides an opportunity to combine varenicline and bupropion SR and capitalize on the potential additive benefit. The investigators hypothesize that this will further increase long-term (≥ 6 months) smoking abstinence rates. Condition or disease Intervention/treatment Phase Smoking Drug: Varenicline Drug: placebo Drug: bupropion SR Phase 2 Phase

2009 Clinical Trials

18. Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers

Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers (ConNic5) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01806779 Recruitment Status : Completed First Posted : March 7, 2013 Results First Posted : October 8, 2015 Last Update Posted : January 18, 2016 Sponsor: Duke University

2013 Clinical Trials

19. Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women

Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women (BIBS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02188459 Recruitment Status : Recruiting First Posted : July 11, 2014 Last Update Posted

2014 Clinical Trials

20. Bupropion reduces some of the symptoms of marihuana withdrawal in chronic marihuana users: a pilot study. Full Text available with Trip Pro

Bupropion reduces some of the symptoms of marihuana withdrawal in chronic marihuana users: a pilot study. Bupropion's (Zyban(®) SR) effectiveness to treat symptoms experienced in marihuana withdrawal was tested in a double-blind, placebo-controlled study with chronic, heavy marihuana users. Participants maintained their usual marihuana intake until Quit Day after which they were required to cease intake of THC products for 14 days. A Withdrawal Discomfort Score revealed that for 7 days (...) immediately following cessation, placebo-treated subjects reported more symptoms than bupropion-treated subjects. Self-reported craving for marihuana increased for the placebo-treated group but not for those treated with bupropion. Measures of sleep and cognitive performance were not different between the two groups. Participants in the bupropion treatment arm were more likely to complete the study than those randomized to the placebo arm (50% completion for bupropion vs. 33% completion for placebo

2012 Substance abuse : research and treatment Controlled trial quality: uncertain